Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful ...

Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research ...

On Dec. 7, Adaptive Biotechnologies presented new data at ASH 2024 showcasing clonoSEQ MRD testing advances and its role in ...

Company announced the commencement of an underwritten public offering of $300M of the company’s ordinary shares, ...

NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS; “NewAmsterdam” or the “Company”), a late-stage, clinical biopharmaceutical company developing oral, non-statin medicines for patients at risk of ...

Serge Belanger, an analyst from Needham, maintained the Buy rating on NewAmsterdam Pharma Company (NAMS – Research Report). The associated ...

NewAmsterdam Pharma’s cardio drug succeeded in a third readout this year, showing that obicetrapib could lower a type of ...

NewAmsterdam Pharma (Nasdaq: NAMS) took a commanding leap in the stock market, thanks to the announcement of positive topline data from its Phase 3 BROADWAY clinical trial. This trial evaluated ...

Data from Eli Lilly and AstraZeneca could help doctors decide treatment order in chronic lymphocytic leukemia. Elsewhere, ...

The findings add to evidence that the company’s drug, obicetrapib, could change the narrative surrounding a once-abandoned ...

Check the time stamp on this data. Updated AI-Generated Signals for Newamsterdam Pharma Company N.v. Warrant (NAMSW) ...

NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) revealed topline data from its Phase 3 BROADWAY clinical trial evaluating ...